buy lower pt reflect gener
risk reiter buy given valuat upsid
messag recent receiv paragraph iv notic letter msn
pharmaceut file anda gener cabometyx challeng salt/
polymorph formul method use patent expir base
review cabometyx ip patent attorney think gener launch
repres unlik bear case loe realist base
case view incorpor pos-adjust scenario gener entri
maintain buy rate given current valuat discount balanc sheet
flexibl pipelin option pt
recent receiv paragraph iv p-iv certif notic letter msn
pharmaceut file anda gener version cabometyx msn
notic letter challeng us patent number salt polymorph form
cabozantinib expir tablet formul cabometyx expir
method treat liver cancer cabometyx expir
method treat kidney cancer cabometyx expir notic
challeng outstand us patent number method use expir
cover cabometyx composit matter expir august
august unlik bear case gener cabometyx launch base review
patent pharmaceut patent attorney loe sometim
realist base case scenario view base review
cabometyx ip see three possibl outcom respect p-iv
challeng time potenti gener cabometyx launch us bear case
highli unlik gener launch august upon expir composit
matter patent patent expir found invalid non-
infring bull case gener cabometyx launch also highli unlik
view prevail court patent found valid infring base
case like outcom view gener cabometyx launch sometim
upon settlement gener challeng and/or implement success
life-cycle extens strategi differ formul issuanc addit patient
etc base analysi see use probability-weight valuat
method account cabometyx loss exclus loe variou time
composit matter patent polymorph patent yield impli
valuat per share assum loe
respect also appli po
year respect new pt per share previous calcul via
pos-weight averag previously-ment impli valuat depend
loe year account addit label extens opportun cabometyx
pipelin asset view sourc potenti upsid valuat
spoke pharmaceut patent attorney believ one first
decis may face whether sue msn time potenti
lawsuit normal innov compani window potenti lawsuit
would automat trigger stay anda would block
receiv regulatori approv case howev stay irrelev given
composit matter patent cabometyx expir
provid addit market exclus least year vastli exceed
stay window patent attorney see three potenti legal strategi
move forward believ strong case could still sue msn
near term address futur uncertainti around ip seek delay gener
cabometyx entri could potenti wait earli file lawsuit hope
page analyst certif import disclosur
injunct temporari restrain order msn case head toward
potenti resolut settlement typic take year file potenti
earli howev attorney caveat certainti judg may
grant injunct tro scenario may also choos sue msn
gener addit ip protect within next year could potenti
prolong strengthen cabometyx exclus
patent attorney believ issu formul use patent expir
hold minim valu wherea sever potenti avenu
success defend polymorph patent major caveat
imposs predict potenti strength patent point time
without insight detail paragraph iv notic letter msn argu
case know specif judg potenti lawsuit takeaway includ
patent tablet formul treatment
rcc treatment expir may narrow scope provid
adequ protect gener formul patent refer
specif tablet excipi weight content cellulos lactos
hydroxypropyl cellulos specif rang ingredi provid limit
scope protect accord attorney gener manufactur could
potenti bypass patent either chang weight content one
excipi per tablet use cellulos switch ingredi
sucros instead lactos long gener version maintain bioequival
brand
polymorph patent similarli narrow scope innov compani
gener multipl avenu defend patent polymorph patent
claim specif crystallin structur l-malat salt cabozantinib form
character specif x-ray powder diffract spectrum xrpd
defin specif locat characterist peak without fulli know physic
chemistri cabozantinib -malat attorney highlight gener way
success defend polymorph patent typic challeng via non-
infring strategi oppos invalid includ gener manufactur
argu infring patent make non-cryst amorph form
cabozantinib -malat may argu gener manufactur process
alway gener trace amount patent-protect crystallin form even
amount present undetect gener manufactur argu
make differ crystallin form cabozantinib -malat exampl one
character differ diffract spectrum may choos argu
crystal stabl form crystallin amorph form eventu
alway convert crystallin form convers theori ultim howev
attorney character potenti protect polymorph patent modest
clearli caveat lack detail
pipelin option trade forward ev/ multipl
discount smidcap biotech peer certainli appreci uncertainti
respect competit risk cabometyx street consensu estim said
high profit balanc sheet flexibl pipelin option warrant higher multipl
line peer view evalu cabometyx
opdivo front-lin kidney cancer vs sutent read interim data
convict trial potenti success given strong mechanist
rational combin inhibitor vs tki link though recent
success competitor tki combin rcc could repres key
competit bar commerci uptak beyond run phase trial
rog-sw liver cancer cabo nivolumab /- ipilimumab
also run signal-find phase ib trial recent ad lung
prostat cancer cohort link inform go-phas decis move forward
meantim clinical-stag continu phase studi initi
current cash balanc sheet gener
free cash flow per year near term base estim provid manag
signific strateg flexibl conduct busi develop grow pipelin
extern thu far management taken conserv approach bd transact in-
licens earli stage asset low up-front payment signific long-term potenti
discoveri preclin program underway four collabor
page analyst certif import disclosur
includ invenra stemsynergi icon aurigen least year remain
cabometyx loe absolut bear case scenario think manag still
suffici time add later develop stage candid pipelin could
potenti provid mid-term growth driver compani
page analyst certif import disclosur
valuat risk
valu inc per share previous use dcf base valuat method
valuat includ commerci product cabometyx cometriq well probability-
adjust cash flow deriv compani pipelin royalti out-licens program
use discount rate termin growth rate appli termin year
post-assum gener entri cabozantinib
risk valuat inc includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
